Torquil Jackson

Torquil is an investment analyst for Cancer Research Horizons. He identifies and evaluates high-impact oncology investments and supports entrepreneurial Cancer Research UK investigators in developing potential start-ups to accelerate their scientific breakthroughs. He currently sits as an observer on the board of Verinnogen Limited. 

Torquil joined Cancer Research Horizons in 2020, working in Business Development roles prior to joining the specialist Ventures team in 2023. Prior to Cancer Research Horizons, Torquil completed his BSc in pharmacology, PhD in the neurobiology of Duchenne muscular dystrophy in the brain, and has published five papers.